Business
Why Mesoblast might be the best ASX healthcare growth share to own right now – Motley Fool Australia
The Mesoblast share price has skyrocketed 260% since March. Here we look at the key drivers behind the gains and whether Mesoblast is a buy.
ASX junior pharmaceutical company Mesoblast Limited(ASX: MSB) is one of the few companies to have delivered substantial gains to its shareholders during 2020. While big name healthcare shares like Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL) have struggled throughout the COVID-19 pandemic, the Mesoblast share price has risen over 80% so far this year. It is also up an astounding 263% since bottoming out at $1.02 back in late March.
What’s been driving the Mesoblast share price?
Mesob…
-
Noosa News11 hours agoTeenage girl killed in alleged hit-and-run at Margate north of Brisbane
-
Noosa News10 hours agoTeenage girl dies in hit-and-run, police hunt for ute
-
Noosa News5 hours ago‘Beyond devastated’ Brisbane family learn missing German shepherd Arnie found dead in back of stolen car
-
Noosa News24 hours agoNRL legend Trevor Gillmeister charged with assaulting police officer at Brisbane pub